Target family: PIM family (type: enzyme)
Target: Pim-3 proto-oncogene, serine/threonine kinase

Ligand: AZD1208 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.640000343322754 pKi
Reference (Journal): Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.
Published in: ACS Med Chem Lett

Ligand: compound 14k [PMID: 21982499] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.070000171661377 pIC50
Reference (Journal): 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
Published in: Bioorg Med Chem Lett

Ligand: compound 1a [PMID: 24900749] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.820000171661377 pIC50
Reference (Journal): Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.
Published in: ACS Med Chem Lett

Ligand: compound 20 [PMID: 22136433] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.050000190734863 pIC50
Reference (Journal): 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
Published in: J Med Chem

Ligand: CX-6258 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Reference (Journal): Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.
Published in: ACS Med Chem Lett

Ligand: dapolsertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Novel benzimidazole derivatives as kinase inhibitors

Ligand: GDC-0339 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.699999809265137 pKi
Reference (Journal): Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.
Published in: J Med Chem

Ligand: LGB321 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 12.100000381469727 pKi
Reference (Journal): Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Published in: Clin Cancer Res

Ligand: nuvisertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.380000114440918 pKi
Reference (Journal): A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
Published in: Neoplasia

Ligand: PIM447 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 11.050000190734863 pKi
Reference (Journal): Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
Published in: J Med Chem

Ligand: SGI-1776 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.159999847412109 pIC50
Reference (Journal): Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.
Published in: J Med Chem

Ligand: uzansertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.920000076293945 pIC50
Reference (Journal): Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Published in: PLoS ONE